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Abstract Multiple sclerosis (MS) is an autoimmune demye-
linating disease of the central nervous system (CNS). Four
distinct disease courses are known, although approximately
90 % of patients are diagnosed with the relapsing-remitting
form (RRMS). The name “multiple sclerosis” pertains to the
underlying pathology: the presence of demyelinating plaques
in the CNS, in particular in the periventricular region, corpus
callosum, cervical spine, and the cerebellum. There are ongo-
ing efforts to discover biomarkers that would allow for an
unequivocal diagnosis, assess the activity of inflammatory
and neurodegenerative processes, or warn of disease progres-
sion. At present, small noncoding RNA particles-microRNA
(miRNA, miR) seem to be particularly noteworthy, as they
take part in posttranscriptional regulation of expression of
various genes. Changes in composition as well as function
of miRNA found in body fluids of MS patients are subjects of
research, in the hope they prove accurate markers of MS
activity. This preliminary study aims to evaluate the expres-
sion of selected extracellular microRNA particles (miRNA-
let-7a, miRNA-92a, miRNA-684a) in patients experiencing
MS relapse and remission, with healthy volunteers serving as
a control group and to evaluate the correlation between
miRNA expression and selected clinical parameters of those
patients. Thirty-seven patients suffering fromMS formed two
examined groups: 20 patients undergoing relapse and 17 in
remission. Thirty healthy volunteers formed the control group.
All patients who were subjects to peripheral blood sampling
had been hospitalized in the Department of Neurology and
Stroke1. Four milliliters of venous whole blood had been
collected into EDTA tubes. The basis for the selection of the
three particular miRNA investigated in this study (miRNA-
let-7a, miRNA-92a, miRNA-684a) was a preliminary bioin-
formatic analysis of data compiled from several medical da-
tabases, including Ovid MEDLINE®, Embase, Cochrane
Database of Systematic Reviews (CDSR), miRWalk, and
miRBase. The isolation of extracellular microRNA from plas-
ma was carried out using miRNeasy Mini Kit (Qiagen) re-
agents. The reverse transcription was carried out with
TaqMan® MicroRNA Reverse Transcription Kit (Applied
Biosystems), as per manufacturers’ instructions. Standard
microRNA TaqMan® tests (Applied Biosystems) were used
for miRNA quantification. The qPCR were performed on a
7900 HT Fast Real-Time PCR System (Applied Biosystems)
and analyzed using Sequence Detection System 2.3 software.
In addition, all patients at the Department of Neurology and
Stroke undergo a routine complete blood count with differen-
tial. The main objective of this study was to evaluate the
expression of selected microRNA (has-miR-let-7a, miR-92a,
and miR-648a) in the plasma of patients with MS during a
relapse as well as in remission and attempt to correlate the
acquired data with clinically relevant parameters of the
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disease. Finding such correlations may potentially lead to the
use of miRNA as a biomarker of MS, which could help
diagnose the disease and assess its severity and the efficacy
of treatment. The difference in the expression of has-miR-let-
7a in the remission group and the control group was statisti-
cally significant (p=0.002). Similarly, the expression of
miRNA-648a in patients in remission was significantly differ-
ent from the expression in the control group (p=0.02).
Analysis of the correlation between the expression of
miRNA-92a and the severity of the disease as measured by
the EDSS scale in patients undergoing relapse showed signif-
icant negative linear correlation (r=−0.54, p=0.01). Higher
miR-648a expression correlated with more frequent flare-ups
in the joint group of patients in remission and relapse (p=
0.03). This study is one of the few that demonstrate signifi-
cantly changed expression of selected extracellular miRNA in
plasma of MS patients and correlate those findings with
clinical parameters. These observations may suggest that
some miRNA subsets may be potential biomarkers for MS
activity.
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Introduction
Multiple sclerosis (MS) is a chronic inflammatory-
demyelinating disease of the central nervous system (CNS),
characterized by focal damage to oligodendrocytes, axonal
and neuronal degeneration, and typical demyelinating plaque
formation in the CNS. The name “multiple sclerosis” pertains
to the underlying pathology: the presence of demyelinating
plaques in the CNS, in particular in the periventricular region,
corpus callosum, cervical spine, and the cerebellum. The
prevalence in Poland is 40–60 per 100,000 people
(Kulakowska et al. 2010). The disease’s onset is typically
between 20 and 40 years. Women are affected twice as often
as men. Lublin and Reingold classification describes four
disease courses: relapsing-remitting MS (RRMS), primary-
progressive MS (PPMS), secondary-progressive MS
(SPMS), and progressive-relapsing MS (Lublin and
Reingold 1996).
Symptoms of MS are manifold and are a result of damage
to various parts of the central nervous system, from the spinal
cord to the brain cortex. In 85 to 90 % of patients, the disease
first manifests as a clinically isolated syndrome (CIS). This
term describes the first episode of neurologic symptoms
caused by inflammatory or demyelinating lesions in the
CNS (Kappos et al. 2006; Optic Neuritis Study Group
1997). Spastic paresis of upper and lower limbs is a typical
symptom and may manifest only during exacerbations or
between them if the recovery of function is not complete.
Approximately 70 % of patients experience some degree of
spasticity, most commonly of the lower limbs (Barnes et al.
2003). Brain stem and cerebellar symptoms include dizziness
and vertigo, dysarthria, nystagmus, ataxia, gait instability,
dysmetria, and dysdiadochokinesia. Bladder dysfunction oc-
curs in around 75 % of MS patients. Patients experience
urinary retention, incontinence, or a combination of both of
the above (Del Popolo et al. 2008). Cognitive impairment and
mental disorders including but not limited to clinical depres-
sion, bipolar disorder, short-term memory loss, attention def-
icit, verbal fluency deficit, poor visual-spatial ability, and
chronic fatigue syndrome are found in over 65 % of patients
(Krupp et al. 1995). The etiology remains unknown. The
disease is most likely caused by complex interactions between
environmental and genetic factors, which lead to an impaired
immune response, resulting in the destruction of myelin
sheaths, oligodendrocytes, axons, and neurons, as well as the
formation of characteristic areas of demyelination (plaques) in
the central nervous system (Sospedra and Martin 2005).
Experimental autoimmune encephalomyelitis (EAE), induced
by immunization with myelin antigens, provides an animal
model for multiple sclerosis. EAE research proves that demy-
elinating lesions in the CNS are a result of autoaggression.
Recent discoveries indicate that IL-17 producing Th lympho-
cytes (Th17) play a special role in the pathogenesis of auto-
immune disorders such as MS and EAE (Bartel 2004).
Though multiple sclerosis (MS) is a chronic inflammatory-
demyelinating disease of the CNS of considerable prevalence
in the Polish population, featuring a varied symptomatology
and unclear etiology, research on the cellular and molecular
level is constantly progressing towards a better understanding
of the disorder.
Extracellular miRNA as Biomarkers of Multiple Sclerosis
There are ongoing efforts to discover biomarkers that would
allow for fast and accurate diagnosis, prophylaxis, monitoring
of the activity of inflammatory and neurodegenerative pro-
cesses as well as the degree of activation of patient’s immune
system. At present, a group of endogenous, single-stranded
noncoding RNA, or miRNA, draws researchers’ close atten-
tion. miRNA constitute the largest group of short regulatory
RNA particles. They were first described in nematodes, then
in fruit flies, fish and mice (Alvarez-Garcia and Miska 2005;
Williams 2008). In mammals, miRNA play an enormous role
in both physiological and pathological processes, such as cell
differentiation, angiogenesis, apoptosis, inflammation, neuro-
logical disorders, and bacterial and viral infections, among
others (Alvarez-Garcia and Miska 2005; Denli et al. 2004;
Williams 2008). miRNAs are processed from precursor
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molecules (pri-miRNAs) which could be transcribed by RNA
polymerase II from their own independent genes or derived
from introns of protein-coding genes. In the case of the former,
the primary transcript is processed with the Drosha enzyme
into 60–80 nucleotide-long miRNA precursors (pre-
miRNAs). The Drosha type-III RNase generates a double
stranded RNA with a phosphate group at the 5′-end and a
hydroxyl group and two unpaired nucleotides at the 3′-end
(Bohnsack et al. 2004). In the latter case, splicing and
debranching of very short introns (mirtrons) occurrs and pre-
miRNAs are produced without the Drosha step (Krol et al.
2010). After initial processing in the nucleus, the 20–22
nucleotide-long pre-miRNA are then exported to the cyto-
plasm by the complex of Exportin 5 (Exp5) and Ran-GTP
(Bohnsack et al. 2004; Schwarz et al. 2003). A Dicer enzyme
cleaves the molecules, which then form RNA-induced silenc-
ing complexes (RISC) (Tomari et al. 2004). By attaching
themselves to complementary sequences of the target RNA,
the RISC complexes improve their stability and help in
mRNA translation. miRNA inhibits protein synthesis by
interacting with partially complementary regions near the 3′-
end, which do not undergo translation. microRNA controls
the expression of many genes, but it merits attention that
particular miRNAmolecules are capable of regulating specific
mRNA. Conducted studies indicate the important role of small
noncoding miRNA as growth, differentiation, and apoptosis
regulators for selected cell lines of the immune system
(Gandhi et al. 2013). This is achieved by affecting transcrip-
tion factors, proapoptotic proteins, and signal transduction
pathways (Gandhi et al. 2013). A positive correlation has been
shown between changes in miRNA expression and the devel-
opment of autoimmunity (Lehmann et al. 2012). Perhaps most
importantly, miRNA abnormalities can be studied by
assessing changes in freely circulating extracellular miRNA
(Lehmann et al. 2012).
Materials and Methods
Patients
Thirty-seven patients suffering fromMS agreed to take part in
the study, with 20 patients undergoing a relapse without
treatment (19 women and 1 man) and 17 in remission without
treatment (15 women and 2 men). Thirty healthy volunteers
(18 women and 12 men) formed the control group. Detailed
patients’ histories were taken, especially concerning MS, and
included early symptoms, year of diagnosis, presentation in
the first year upon diagnosis, number of relapses and hospi-
talizations, management, familial antecedents, and comorbid-
ities. Neurological exams were performed to assess patients
using the Expanded Disability Status Scale (EDSS).
The Isolation of Blood Plasma
Four milliliters of venous blood were collected at a time and
put into EDTA tubes. After centrifugation was undertaken to
obtain plasma, all biologic material was stored at −80 °C to
await analysis. The blood was centrifuged (5000 rpm, 20 min,
23 °C), and later the top layer containing plasma was carefully
moved into test tubes (2×2 ml). The tubes of plasma labeled
with patient’s individual identification numbers were then
stored at −80 °C on the premises of the Department of
Neurology and Stroke Unit. Actual analyses took place in
the Central Laboratory of the Medical University of Lodz.
miRNA Selection
A bioinformatic analysis identified three extracellular miRNA
molecules as good potential candidates for markers of MS
(miRNA-let-7a, miRNA-92a, miRNA-684a). They correlated
well with MS progression as well as markers of inflammation,
such as IL-17 and IL-7, among others, while IL-7 is also
implicated in the pathogenesis of MS. The following data-
bases were used: Ovid MEDLINE®, Embase, Cochrane
Database of Systematic Reviews (CDSR), miRWalk, and
miRBase (Griffiths-Jones et al. 2008; Dweep et al. 2011).
miRNA Expression Analysis
The isolation of extracellular microRNA from plasma was
carried out using miRNeasy Mini Kit (Qiagen) reagents. A
0.2-ml plasma was added to 1 ml of QIAzol reagent, shaken
vigorously, and incubated for 5 min at room temperature to
promote a complete dissociation of nucleoprotein complexes.
Subsequently, 25 fmols of Caenorhabditis elegans miRNA-
39 mimic (cel-miRNA-39) were added to serve as an exoge-
nous, “spiked-in” control of the purification efficiency. After
adding 320 μl of chloroform to separate the aqueous and
phenolic phases, the homogenate was vigorously shaken for
45 s and stored for 5 min at room temperature. After centrifug-
ing at 14,000g for 20min, total RNAwas precipitated from the
aqueous phase using 100 % ethanol. The purification of total
RNA was achieved using QuiagenmiRNeasy spin columns
according to the protocol provided by the manufacturer. The
RNA was then eluted from the column by adding 30 μl of
RNase-free water.
The reverse transcription of 5 μl of the eluate in a 15-μl
reaction was carried out using a TaqMan® MicroRNA
Reverse Transcription Kit (Applied Biosystems), as per the
manufacturers’ instructions. The standard MicroRNA
TaqMan® tests (Applied Biosystems) used for miRNA quan-
tification were the following: HSA-let-7a (test ID: 000377),
HSA-miR-92a (test ID: 000431), HSA-miR-648A (test ID:
001601), as well as cel-miR-39 (test ID: 000200) as control.
The 20-μl reaction mix required for the quantitative PCR
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contained 1.33μl of the product from the RT reaction, 10μl of
TaqMan Universal PCRMaster Mix, 1 μl of TaqMan miRNA
assay (20×), and nuclease-free water. Reaction plates were
incubated in a 96-well thermal cycling plate at 95 °C for
10 min and then underwent 40 cycles of 15 s at 95 °C and
1 min at 60 °C. All reactions were performed in duplicate.
The qPCR were performed on a 7900 HT Fast Real-Time
PCR System (Applied Biosystems) and analyzed using
Sequence Detection System 2.3 software. Relative quantita-
tion (RQ) was calculated using the 2−ΔCt method, whereΔCt
symbolized the difference of Ct between sample and reference
miRNA.
Blood Count Analyses
All 37 patients participating in the study also underwent a
complete blood count, as part of the routine diagnostic panel
for every MS patient at the Central Veterans’ Teaching
Hospital No. 2. Whole blood was collected into tubes con-
taining an anticoagulant (EDTA) by the nursing staff of the
Department of Neurology and Stroke in Lodz per doctor’s
request and analyzed in the hospital lab. The specific equip-
ment used was Siemens ADVIA 2120i, according to the
manufacturer’s protocol.
Statistical Analysis
Nominal variables were given as numbers with appropriate
percentage whereas continuous variables as means with stan-
dard deviation. The normality of distribution was verified
using the Shapiro-WilkW test. Grubbs’ test was used to detect
outliers. Differences between both groups were analyzed
using the nonparametric Mann-Whitney U test. In the case
of a higher number of groups, a nonparametric Kruskall-
Wallis ANOVA test was used instead. In order to evaluate
the correlation between variables, Spearman’s rank correlation
coefficient was used. P values of <0.05 were considered to be
statistically significant. The entire statistical analysis was car-
ried out using Statistica 10.0 software by Statsoft.
Results
Plasma Levels of Selected Extracellular microRNA
The normality of distribution of examined microRNA (miR-
let-7a, miR-648a, miR-92a) was assessed using the Shapiro-
Wilk test. The resulting p value (p<0.05) allowed for the
rejection of the null hypothesis, and nonparametric tests were
used for subsequent analyses.
There was a statistically significant difference in the ex-
pression of miR-let-7a among all groups included in the
analysis (Kruskal-Wallis ANOVA p=0.0035). A detailed
analysis of relationships in subgroups revealed a statistically
significant difference in expression levels of miR-let-7a—in
patients in remission, the relative expression was lower than in
the control group (Kruskal-Wallis ANOVA p=0.002), where-
as the remaining analyses were not statistically significant
(Fig. 1).
The expression of miR-648a in all analyzed groups was
also significantly different (Kruskal-Wallis ANOVA p=
0.024). The expression of miR-648a in patients in MS remis-
sion was lower than in the control group (Kruskal-Wallis
ANOVA p=0.02), whereas the remaining analyses were not
statistically significant (Fig. 2).
The combined analysis of all three groups shows no sig-
nificant difference in the expression of miR-92a (p=0.19).
Further analyses between subgroups showed no statistically
significant differences (p=0.24 for comparison between re-
mission and control groups, p=0.94 for comparison between
relapse and control groups, and p=0.43 for comparison be-
tween remission and relapse groups) (data not shown).
Analysis of Correlation Between the Expression of Selected
microRNA and Severity of the Disease
The presented study attempted to correlate relative levels of
expression of selected miRNAwith the severity of MS symp-
toms, as measured by the EDSS. Analyses were performed for
relapse and remission subgroups, as well as the joint group of
all patients (in relapse and remission). A statistically signifi-
cant correlation was found between the relative expression of
miR-92a and the EDSS in the relapse group. The observed
result was a negative linear correlation (Spearman’s rank
correlation, p=0.01) (Fig. 3).
A positive linear correlation between the EDSS score and
miR-92a expression in the remission group was also noted,
although it was not statistically significant (Spearman’s rank
correlation, p=0.39) (Fig. 4).
A negative linear correlation between the EDSS score and
miR-92a expression in the joint group of patients (relapse and
remission together) was noted. It was not statistically signifi-
cant (Spearman’s rank correlation, p=0.56) (Fig. 5).
Analysis of Correlation Between the Expression of Selected
microRNA and Cumulative Number of Relapses
Two distinct patterns have been observed upon the analysis of
the number of flare-ups that patients have undergone and the
expression of selected miRNA: lower miR-92a expression
tended to correlate with more frequent flare-ups in the group
of patients in remission (Spearman’s rank correlation, p=0.1),
while higher miR-648a expression tended to correlate with
more frequent flare-ups in the group of patients in relapse
(Spearman’s rank correlation, p=0.09, Fig. 6). In the group of
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patients in remission, this tendency was also observed but it
was weaker (Spearman’s rank correlation, p=0.24; Fig. 7).
The latter of the described correlations also holds true and is
statistically significant when applied to the joint group of
patients in remission and relapse (p=0.03; Fig. 8).
Analysis of Correlation Between WBC and Their
Subpopulations (Lymphocytes, Neutrophils and Monocytes)
and Relative Expression of Selected microRNA
All patients underwent a complete blood count with a WBC
differential. Abnormalities of these lab results can stem from
therapy itself or from coinciding pathologies, e.g., acute
infections. An attempt to correlate WBC counts (in total as
well as specific fractions) with relative expression of miRNA
was made. No statistically significant correlations were found.
The results are presented in Table 1.
Discussion
The search for an ideal marker of multiple sclerosis is still
underway. As of yet, a molecule that would allow a quick and
precise diagnosis, as well as the monitoring of the immune
and pathological processes, has not been found. Currently, a
Fig. 1 Expression of miR-let-7a
in all analyzed groups, as
described in Materials and
Methods
Fig. 2 Expression of miR-648 in
all analyzed groups, as described
in Materials and Methods
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group of endogenous, single-stranded noncoding RNA mole-
cules, or microRNA (miRNA, miR), shows promise. It is the
best known class of noncoding regulatory RNA to date. They
are described as multifunctional molecules, as they are in-
volved in both physiological as well as pathological processes.
In the presented study, three selected extracellular microRNA
molecules were investigated (miRNA-let-7a, miRNA-92a,
and miRNA-648a) in patients in remission or undergoing a
relapse of MS.
This study identified a member of the let-7 family, the hsa-
let-7a, which helped differentiate the relapsing-remitting form
of MS (RRMS) from the healthy control group (HC). In the
case of miR-let-7a, there was a statistically significant
difference in the expression across all of the groups involved
in the study (p=0.0035). A detailed analysis of the relation-
ships in the subgroups revealed a significantly lower expres-
sion of miR-let-7a in the group of patients in remission com-
pared to the control group (p=0.002). In other cases, the
differences were not statistically significant. In none of the
studied groups, miR-let-7a correlates with patients’ EDSS
scores; this could indicate that levels of miR-let-7a found in
plasma are not a reliable marker of patients’ clinical condition.
Previous studies focusing on extracellular miRNA-let-7a de-
termined that these molecules were potent activators of Toll-
like receptors (TLR) in macrophages and microglia (Roush
and Slack 2008) and that they took part in cellular signaling,
Fig. 3 Correlation between miR-
92a relative quantitation (RQ) and
MS severity (EDSS scores) in
patients with MS relapse
Fig. 4 Correlation between miR-
92a relative quantitation (RQ) and
MS severity (EDSS score) in
patients in MS remission
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activation of stem cells, and neurogenesis (Swaminathan et al.
2012). Moreover, they were also involved in the regulation of
the expression of anti-inflammatory cytokines, such as IL-10
and IL-13, in T cells in patients with MS (Kaushansky et al.
2010).
The analysis of miRNA-648a revealed a statistically sig-
nificant difference in the expression between all the groups
involved in the study (p=0.024).A detailed analysis of the
relationships in the subgroups revealed a significantly lower
expression of miR-let-7a in the group of patients in remission
compared to the control group (p=0.02). miR-648a RQ com-
parisons between the remission and relapse groups (p=0.12)
as well as between the relapse and control groups (p=0.67)
proved to be insignificant. The study investigated the potential
link between the relative expression of selected miRNA and
the severity of MS symptoms, as measured by the EDSS
score. In the case of miR-648a, no such correlation was
observed.
Another observed tendency was for a higher expression of
miR-648a in patients with a history of more frequent flare-ups
within the relapse group (p=0.09). This correlation is statisti-
cally significant in a joint analysis of patients in relapse and
remission together (p=0.03). The function of miR-648a is to
modula t e the expres s ion of mye l in -as soc i a t ed
Fig. 5 Correlation between miR-
92a relative quantitation (RQ) and
MS severity (EDSS score) in
combined groups of MS patients
(relapse + remission)
Fig. 6 Correlation between miR-
648a relative quantitation (RQ)
and cumulative number of
relapses in patients undergoing
MS relapse
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oligodendrocyte basic protein (MOBP) and the NR2C2 ste-
roid nuclear receptor (Doi et al. 2008; Kaushansky et al.
2010). Changes in myelin-associated oligodendrocyte basic
protein are seen in the pathogenesis of MS (Doi et al. 2008),
while changes in NR2C2 affects the modulation of NR4A2.
This is expressed in the T cells of MS individuals and acts as
an essential transcription factor for triggering the production
of inflammatory cytokines inMS (Doi et al. 2008; Siegel et al.
2012; Tsuchida et al. 2011). Increased expression of miRNA-
648a in plasma might lead to decreased expression of MOBP,
which in turn could be responsible for the reduction of
durability and continuity of myelin sheaths in the CNS (Doi
et al. 2008; Siegel et al. 2012; Tsuchida et al. 2011). It was
therefore speculated that this miRNA targets FOXD1, a mem-
ber of the forkhead homeobox/winged helix family of tran-
scription factors (Tsuchida et al. 2011).
No statistically significant differences in the expression
across all studied groups were found concerning the third
analyzedmiRNA—the miR-92a (p=0.19). Similarly, compar-
isons of its relative expression in relapse vs. remission group
(p=0.43), remission vs. control group (p=0.24), and relapse
vs. control group (p=0.94) proved insignificant. Detailed
Fig. 7 Correlation between miR-
648a relative quantitation (RQ)
and the number of relapses in MS
patients in remission
Fig. 8 Correlation between miR-
648a expression and cumulative
number of relapses in combined
group of all MS patients
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analyses of correlation were carried out in all subgroups,
including a joint group of patients in remission and in relapse
together. The only statistically significant observation was a
negative linear correlation between miR-92a RQ and the
EDSS score in the group of patients undergoing anMS relapse
(p=0.01).
An attempt to correlate leukocyte counts (total and subpop-
ulations) with relative expression levels of the studied miRNA
was made (Table 1). No statistically significant results were
obtained, which may signify that changes in WBC counts
(which could be attributed to the MS therapy as well) did
not influence the observed expression levels of the studied
miRNA.
Previous studies demonstrate that miR-92 targets CD40
signaling pathways, which were found to be upregulated in
RRMS disease. Those targets are involved in cell cycle regu-
lation and belong to the miR-17-92 miRNA cluster (Balashov
et al. 1997; Gandhi et al. 2013; Juntilla and Koretzky 2008;
Xiao et al. 2008). Differential expression of the miR-17-92
cluster had previously been reported in relation to cancers and
in multiple sclerosis, and it is involved in the modulation of
the proliferation and activation of naive CD4+ T cells. It had
also been identified as a contributing factor in the develop-
ment of lymphoproliferative diseases in a murine model of
autoimmunity, where raised counts of CD4+ T cells with an
activated phenotype were noted (Balashov et al. 1997; Gandhi
et al. 2013; Juntilla and Koretzky 2008; Xiao et al. 2008).
Reduced expression of miR-92a has been observed in B cells
of individuals with MS. A pathway potentially regulated by
the miR-17-92 cluster is the PI3K/Akt pathway, known to
regulate different stages of lymphocyte development,
activation, and survival (Fenoglio et al. 2012; Guerau-de-
Arellano et al. 2012; Reid et al. 2011).
miRNA molecules are of growing importance in many
research areas. A thorough understanding of microRNA pro-
files in a given disease may aid in a more quick and accurate
diagnosis. These molecules also appear to be universal prog-
nostic factors. Expression profiles of particular miRNA char-
acterize selected types and stages of MS with a high degree of
specificity. The biological material necessary for such testing
is easy to obtain, since miRNA expression can be evaluated
based on plasma concentrations. This increases the availabil-
ity of research material and makes analyses easier to perform.
The obtained results suggest that extracellular miRNA
are interesting and promising candidates for biomarkers of
multiple sclerosis (MS), although further research is nec-
essary. As had been demonstrated in previous studies,
miRNA expression differs depending on the stage of the
disease (relapse vs. remission), which allows for the in-
ference that these molecules could aid in the early diag-
nosis of the disease. The next essential step is a larger
study on a broader group of patients, representative of
various clinical patterns of MS and other parameters. If
those efforts lead to the discovery of miRNA molecules
with high enough specificity, further studies will be nec-
essary to evaluate their expression not only in MS but
also in other immune-related and neurodegenerative dis-
eases—for example, Parkinson’s disease, where similar
studies are also being conducted (Heman-Ackah et al.
2013). Only then would it be possible to establish how
specific and in turn how useful in clinical practice those
new markers could really be.
Table 1 Comparison of total
WBC counts (total and
subpopulations) with relative










WBC −0.05 0.82 −0.20 0.42 −0.04 0.87
Neutrophils −0.14 0.55 −0.31 0.18 −0.21 0.37
Lymphocytes −0.04 0.86 0.03 0.89 0.35 0.13
Monocytes −0.15 0.54 0.29 0.22 0.25 0.29
Patients in remission
WBC 0.10 0.69 −0.004 0.99 0.14 0.58
Neutrophils 0.20 0.43 0.12 0.63 0.26 0.31
Lymphocytes −0.11 0.68 −0.23 0.38 −0.07 0.80
Monocytes −0.24 0.36 −0.19 0.48 −0.46 0.06
Patients in relapse and remission
WBC 0.05 0.76 0.04 0.83 0.08 0.65
Neutrophils 0.03 0.86 −0.04 0.80 −0.07 0.83
Lymphocytes 0.02 0.91 0.10 0.56 0.24 0.16
Monocytes −0.17 0.30 0.15 0.37 0.03 0.96
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been published before.
Open Access This article is distributed under the terms of the Creative
Commons Attribution License which permits any use, distribution, and
reproduction in any medium, provided the original author(s) and the
source are credited.
References
Alvarez-Garcia I, Miska EA (2005) MicroRNA functions in animal
development and human disease. Development 132(21):4653–4662
Balashov KE, Smith DR, Khoury SJ, Hafler DA, Weiner HL (1997)
Increased interleukin 12 production in progressive multiple sclero-
sis: induction by activated CD4+ Tcells via CD40 ligand. Proc Natl
Acad Sci U S A 94(2):599–603
Barnes MP, Kent RM, Semlyen JK, McMullen KM (2003) Spasticity in
multiple sclerosis. Neurorehabil Neural Repair 17(1):66–70
Bartel DP (2004) MicroRNAs: genomics, biogenesis, mechanism, and
function. Cell 116(2):281–297
Bohnsack MT, Czaplinski K, Gorlich D (2004) Exportin 5 is a RanGTP-
dependent dsRNA-binding protein that mediates nuclear export of
pre-miRNAs. RNA 10(2):185–191
Del Popolo G, Panariello G, Del Corso F, De Scisciolo G, Lombardi G
(2008) Diagnosis and therapy for neurogenic bladder dysfunctions
in multiple sclerosis patients. Neurol Sci 29(4):S352–355
Denli AM, Tops BB, Plasterk RH, Ketting RF, Hannon GJ (2004)
Processing of primary microRNAs by the microprocessor complex.
Nature 432(7014):231–235
Doi Y, Oki S, Ozawa T, Hohjoh H, Miyake S, Yamamura T (2008)
Orphan nuclear receptor NR4A2 expressed in T cells from multiple
sclerosis mediates production of inflammatory cytokines. Proc Natl
Acad Sci U S A 105(24):8381–8386
Dweep H, Sticht C, Pandey P, Gretz N (2011) miRWalk–database:
prediction of possible miRNA binding sites by “walking” the genes
of three genomes. J Biomed Inform 44(5):839–847
Fenoglio C, Ridolfi E, Galimberti D, Scarpini E (2012) MicroRNAs as
active players in the pathogenesis of multiple sclerosis. Int J Mol Sci
13(10):13227–13239
Gandhi R, Healy B, Gholipour T et al (2013) Circulating microRNAs as
biomarkers for disease staging in multiple sclerosis. Ann Neurol
73(6):729–740
Griffiths-Jones S, Saini HK, van Dongen S, Enright AJ (2008) miRBase:
tools for microRNA genomics. Nucleic Acids Res 36(Database
issue):D154–158
Guerau-de-Arellano M, Alder H, Ozer HG, Lovett-Racke A, Racke MK
(2012) miRNA profiling for biomarker discovery in multiple sclerosis:
frommicroarray to deep sequencing. J Neuroimmunol 248(1–2):32–39
Heman-Ackah SM, HalleggerM, RaoMS,WoodMJ (2013) RISC in PD:
the impact of microRNAs in Parkinson’s disease cellular and mo-
lecular pathogenesis. Front Mol Neurosci 6:40
Juntilla MM, Koretzky GA (2008) Critical roles of the PI3K/Akt signal-
ing pathway in T cell development. Immunol Lett 116(2):104–110
Kappos L, Polman CH, Freedman MS et al (2006) Treatment with
interferon beta-1b delays conversion to clinically definite and
McDonald MS in patients with clinically isolated syndromes.
Neurology 67(7):1242–1249
Kaushansky N, Eisenstein M, Zilkha-Falb R, Ben-Nun A (2010) The
myelin-associated oligodendrocytic basic protein (MOBP) as a rel-
evant primary target autoantigen in multiple sclerosis. Autoimmun
Rev 9(4):233–236
Krol J, Loedige I, Filipowicz W (2010) The widespread regulation of
microRNA biogenesis, function and decay. Nat Rev Genet 11(9):
597–610
Krupp LB, Coyle PK, Doscher C et al (1995) Fatigue therapy in
multiple sclerosis: results of a double-blind, randomized,
parallel trial of amantadine, pemoline, and placebo.
Neurology 45(11):1956–1961
Kulakowska A, Bartosik-PsujekH, Hozejowski R,Mitosek-SzewczykK,
Drozdowski W, Stelmasiak Z (2010) Selected aspects of the epide-
miology of multiple sclerosis in Poland—a multicentre pilot study.
Neurol Neurochir Pol 44(5):443–452
Lehmann SM, Kruger C, Park B et al (2012) An unconventional role for
miRNA: let-7 activates Toll-like receptor 7 and causes neurodegen-
eration. Nat Neurosci 15(6):827–835
Lublin FD, Reingold SC (1996) Defining the clinical course of multiple
sclerosis: results of an international survey. National Multiple
Sclerosis Society (USA) advisory committee on clinical trials of
new agents in multiple sclerosis. Neurology 46(4):907–911
Optic Neuritis Study Group (1997) The 5-year risk of MS after optic
neuritis. Experience of the optic neuritis treatment trial. Neurology
49(5):1404–1413
Reid G, Kirschner MB, van Zandwijk N (2011) Circulating microRNAs:
association with disease and potential use as biomarkers. Crit Rev
Oncol Hematol 80(2):193–208
Roush S, Slack FJ (2008) The let-7 family of microRNAs. Trends Cell
Biol 18(10):505–516
Schwarz DS, Hutvagner G, Du T, Xu Z, Aronin N, Zamore PD (2003)
Asymmetry in the assembly of the RNAi enzyme complex. Cell
115(2):199–208
Siegel SR, Mackenzie J, Chaplin G, Jablonski NG, Griffiths L (2012)
Circulating microRNAs involved in multiple sclerosis. Mol Biol
Rep 39(5):6219–6225
Sospedra M, Martin R (2005) Immunology of multiple sclerosis. Annu
Rev Immunol 23:683–747
Swaminathan S, Suzuki K, Seddiki N et al (2012) Differential regulation
of the let-7 family of microRNAs in CD4+ T cells alters IL-10
expression. J Immunol 188(12):6238–6246
Tomari Y, Matranga C, Haley B, Martinez N, Zamore PD (2004) A
protein sensor for siRNA asymmetry. Science 306(5700):1377–
1380
Tsuchida A, Ohno S, Wu W et al (2011) miR-92 is a key oncogenic
component of the miR-17-92 cluster in colon cancer. Cancer Sci
102(12):2264–2271
Williams AE (2008) Functional aspects of animal microRNAs. Cell Mol
Life Sci 65(4):545–562
Xiao C, Srinivasan L, Calado DP et al (2008) Lymphoproliferative
disease and autoimmunity in mice with increased miR-17-92 ex-
pression in lymphocytes. Nat Immunol 9(4):405–414
J Mol Neurosci (2015) 56:154–163 163
